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PERSPECTIVE
Finding chemopreventatives to reduce 
amyloid beta in yeast
Alzheimer’s disease (AD) is the most common form of age-re-
lated dementia with the latest report (WorldAlzheimerReport, 
2015) showing 46.8 million people are currently affected by 
dementia. That number is expected to double every 20 years 
unless there is effective therapeutic intervention.  
The 42 amino acid peptide known as amyloid beta (or Aβ) 
has been implicated as one of the main causative agents of AD 
after its discovery in plaques in 1985 (Masters et al., 1985). Since 
then evidence has accumulated to support the association be-
tween AD and Aβ. 
However, progress to find a cure for AD has been very slow, due 
to lack of reliable models and a lack of understanding about 
what role Aβ plays in AD (reviewed in Moosavi et al., 2015).  
For a period, funding agencies including the Alzheimer’s 
Association and the Alzheimer’s Drug Foundation were turn-
ing away from projects focused on Aβ. To be fair, part of the 
rationale was probably to diversify their portfolio, but certainly 
many have questioned the approaches used in Aβ research.  
Convincing evidence of Aβ being the cause of AD has been 
sought through treatments with therapeutic antibodies that bind 
and remove Aβ. Such treatments include the humanized mono-
clonal antibodies crenezumab (a homologue of bapineuzamab). 
Results in clinical trials with bapineuzumab were initially prom-
ising and showed clearance of brain amyloid and the lowering of 
phosphorylated tau protein in the cerebrospinal fluid, however, 
people did not recover from AD. The failure to cure AD (Panza et 
al., 2012) led many to doubt that Aβ should be the prime target 
for the treatment of AD, resulting in a backlash against research 
on Aβ as a drug target (e.g., see Hyman and Sorger, 2015). The 
recent antibody trial is showing some promise, although it did 
not meet the desired end points (Underwood, 2015).
Two non-exclusive hypotheses for the failures are poor blood- 
brain barrier penetration (0.1%) and treatment of patients who 
progressed too far to recover from the disease. Now the tide may 
turn. A major trial, using people who have no disease but who 
have biomarkers indicating a likely progression to AD, is address-
ing the question of whether therapeutic antibodies against Aβ 
might prevent AD. The early indications are that therapeutic an-
tibodies that clear Aβ can indeed prevent or delay development 
of AD. Aβ appears like it will be in vogue as a target once again!
Therapeutic antibodies are magic bullets for acute diseases 
like cancer. They are very expensive but affordable in a wealthy 
society over the relatively short duration for the treatment of 
acute diseases. But therapeutic antibodies are not the answer 
for prevention of a chronic disease like AD. They are simply not 
affordable, and they appear impractical for extended use. They 
are important in establishing that Aβ is a valid target for ther-
apy but frequent injections and huge on-going cost means that 
long term use as a therapy is not viable.
While a description of all the metabolic pathways of Aβ pro-
duction and clearance is beyond the scope of this perspective, 
(for a review see Zhang et al., 2011), the well documented ben-
eficial effects of statins can be mentioned. Studies have found 
up to a 70 % decreased risk of AD in people taking statins and 
reduced production of Aβ. The stains, originally used as choles-
terol inhibitors are now being used to manage neurodegenera-
tive disorders such as vascular dementia and AD. In a research 
article focusing on effects of Simvastatin in AD, researchers 
demonstrated a differential dose-dependent effect with Sim-
vastatin on hypoxia inducible factor 1α (HIF-1α) and amyloid 
precursor protein cleaving enzyme (BACE) in cultured AD 
cytoplasmic hybrid cells (cybrid cells). These Cybrid cells are 
being used in research to study dysfunctional mitochondria in 
AD pathogenesis (Jeong et al., 2015). 
There is growing interest in naturally derived compounds 
as chemopreventatives to remove Aβ. Such compounds 
should be taken conveniently, which means it is best if they 
can be ingested. Epidemiology suggests there are many com-
pounds in existing foods that may be useful for chemopre-
vention of AD (Pandey and Risvi, 2009). Since we have rea-
sonable ideas about the molecular basis of Aβ, it is important 
that we incorporate these ideas into rational screening for AD 
chemopreventatives.
What do we know about Aβ and what it does? We know that 
Aβ accumulates in brains with age. In yeast we have found that 
young cells, that are newly budded, remove Aβ. Slightly older 
cells also clear it. But the oldest cells, “grand mothers” retain the 
Aβ. We know this from in vitro studies where the Aβ is fused to 
green fluorescent protein (GFP) (see Figure 1). The older cells 
are readily recognized by the presence of multiple bud scars: one 
bud scar is left for every cell budded off. In Figure 1, isogenic 
cells from the same parent can be observed: the older cells with 
multiple bud scars (stained with calcofluor) have accumulated 
Aβ and exhibit green fluorescence. It can also be observed that 
the older cells pass the green fluorescent fusion protein to their 
progeny, and for a brief time the bud is fluorescent, but it rapid-
ly disappears due to increased autophagy in the young cell.  
How do we apply this knowledge? We can screen for com-
pounds that reduce the Aβ related pathology in a cell population. 
Our detailed methods of doing this are recently published (Por-
zoor and Macreadie, 2015). Useful compounds (a) increase clear-
ance of Aβ, or (b) reduce Aβ induced toxicity. Such compounds 
may be useful as chemopreventatives that reduce the level of Aβ, 
and they may have broader benefits for other age-related protein 
misfolding diseases. Laterpiridine is a compound that has some 
history as an AD drug and yeast screening studies show that it 
increases turnover of Aβ (Bharadwaj et al., 2012). It has also been 
shown that pure components of green tea, epigallocatechin gal-
late (EGCG), and salvianolic acid (from the traditional Chinese 
herb, Danshen) lead to reduced levels of Aβ (Porzoor et al., 2015). 
Interestingly in vitro studies also show that EGCG and salvianolic 
acid block fibril formation, suggesting the direct interaction be-
tween amyloid beta and these compounds (Porzoor et al., 2015). 
To explain the in vivo results it would appear that such binding 
targets the Aβ-salvianolic acid complex, or Aβ-EGCG complex 
for degradation. An alternate explanation is that salvianolic acid 
or EGCG might trigger autophagy independently. Either way, the 
Amyloid beta in AD:
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Figure 1 Amyloid beta persists in older yeast cells.  
(A) Two pairs of yeast cells that are budding. (B) Cells producing amyloid beta fused to green fluorescent protein (GFP) and the fluorescence is 
readily observed in older cells as punctate patches. (C) Bud scars that are stained with calcofluor. The young cells receive the fluorescent amyloid 
beta but rapidly remove it (not shown). 
 A    B    C   
removal of Aβ is the desired outcome.
Aβ is cytotoxic as an oligomeric species, and this characteristic 
also lends itself to screening. Such screening can be performed 
using the exogenous addition of chemically-synthesised Aβ. 
However, recently doubts have been created about the prepara-
tion of such peptide (Porzoor et al., 2014). The more common 
hexafluoroisopropanol method results in toxic peptide, but an 
ammonium hydroxide preparation results in Aβ that stimulates 
growth. Which preparation is biologically relevant? Certainly 
cellular toxicity is widely looked at, but stimulation of growth 
may be relevant, since neuronal cells are terminally differentiat-
ed and do not divide, but in AD many neuronal cells are found 
to have entered a cell division cells that has led to their death! 
The more convenient assay is to look for oligomerisation in the 
Aβ fused to green fluorescent protein (GFP). Monomeric Aβ 
fused to GFP will exhibit full fluorescence levels, but the dimeric 
species is not expected to fluoresce. Therefore increasing green 
fluorescence should also be a good outcome. Indeed this is the 
basis of assays developed in E. coli, where all fusion protein is 
non-fluorescent, but fluorescent in the presence of oligomerisa-
tion inhibitors (Park et al., 2011).
The ability of yeast to be used as a tool for screening anti am-
yloidogenic compounds is a useful and unique contribution. It 
can be adapted to high throughput use, it informs about com-
pounds that are bioavailable, and it requires no Aβ preparation. 
In a world that seeks new ways to lower Aβ, the yeast assays 
should be valuable additions to moving forward.
AD chemopreventatives are an economical approach to 
protect the future aging population. The solution will not be a 
single compound but is likely to comprise pharmaceuticals and 
nutraceuticals that not only target Aβ but improve overall cell 
robustness.  
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